Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with ß-Interferon and Inosine Pranobex: Combination Schedule vs Monotherapies

  • Domenico Sansonno
  • Claudio Azzolini
  • Franco Dammacco


The recently identified hepatitis C virus (HCV)1 is responsible for almost 90% of cases of chronic post-transfusion non-A, non-B hepatitis and for more than 70% of sporadic cases2. Acute NANB hepatitis becomes chronic in 50% of cases3 and 20–30% of them progress to cirrhosis4.


Chronic Hepatitis Combination Group Inosine Pranobex NANB Hepatitis Fibroblast Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, M. Houghton, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science 244: 359 (1989).PubMedCrossRefGoogle Scholar
  2. 2.
    D.Sansonno, F. Dammacco, Antibodies to hepatitis C virus in non-A, non-B post-transfusion and cryptogenic chronic liver disease, Lancet ii: 798 (1989).CrossRefGoogle Scholar
  3. 3.
    H.J. Alter, Transfusion-associated non-A, non-B hepatitis: the first decade, in: “Viral hepatitis and liver disease”, A.J. Zuckerman, ed, A.R. Liss, New York (1988).Google Scholar
  4. 4.
    R.L. Koretz, O. Stone, M. Mousa, G.L. Gitnik, Non-A, non-B post-transfusion hepatitis. A decade later, Gastroenterology 88: 1251 (1985).PubMedGoogle Scholar
  5. 5.
    W.H. Caselmann, J. Eisenburg, P.H. Hofschneider, R. Koshy, ß and γ-interferon in chronic active hepatitis B. A pilot trial of short term combination therapies, Gastroenterology 96: 449 (1989).PubMedGoogle Scholar
  6. 6.
    A. Biliau, The clinical application of fibroblast interferon. An overview, Med Oncol & Tumor Pharmacother 1: 87 (1984).Google Scholar
  7. 7.
    K. Ohnishi, F. Nomura, S. Lida, Treatment of post-transfusion non-A, non-B acute and chronic hepatitis with human fibroblast 6-interferon: A preliminary report, Am J Gastroenterol 84: 596 (1989).PubMedGoogle Scholar
  8. 8.
    K. Chayama, S. Saiton, Y. Arase, K. Ikeda, T. Matsumoto, Y. Sakai, M. Kobayashi, M. Unakami, T. Morinaga, H. Kumada, Effect of interferon administration on serum hapatitis C virus RNA in patients with chronic hepatitis C, Hepatology 13: 1040 (1991).PubMedCrossRefGoogle Scholar
  9. 9.
    D.M. Campoli-Richards, E.M. Sorkin, R.C. Heel, Inosine pranobex: a preliminary review of its pharmacodynamics and pharmacokinetics properties, and therapeutic efficacy, Drugs 32: 383 (1986).PubMedCrossRefGoogle Scholar
  10. 10.
    W. Prohasca, K. Kleesiek, Treatment of chronic hepatitis C with inosine pranobex, Lancet 338: 390 (1991).CrossRefGoogle Scholar
  11. 11.
    D. Sansonno, P. Detomaso, M.A. Papanice, G. Fiore, G. Bufano, O.G. Manghisi, Correlation between hepatitis B virus deoxyribonucleic acid and receptors for polymerized human albumine in HBV chronic infection, Digestion 37: 206 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    G.L. Davis, L.A. Balart, E.R. Schiff, K. Lindsay, H.C. Bodenheimer, R.P. Perrillo, W. Carey, I.M. Jacobson, J. Payne, J.L. Dienstag, D.H. Vanthiel, C. Tamburro, J.Lefkowitch, J. Albrecht, C. Meschievitz, T.J. Ortego, A.Gibas, Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321: 1501 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    X. Causse, H. Godinot, M. Chevallier, P. Chossegros, F. Zoulin, D. Ouzan, J-P. Heyraud, T. Fontanges, J. Albrecht, C. Meschievitz, C. Trepo, Comparison of 1 or 3 MU of Interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101: 497 (1991).PubMedGoogle Scholar
  14. 14.
    D. Sansonno, V. Cornacchiulo, P. Gatti, F. Dammacco, Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during ß-interferon therapy of hepatitis C virus-associated chronic active disease, Int J Clin Lab Res 22: 100 (1992).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Domenico Sansonno
    • 1
  • Claudio Azzolini
    • 1
  • Franco Dammacco
    • 1
  1. 1.Department of Biomedical Sciences and Human Oncology Section of Internal Medicine and Clinical OncologyUniversity of Bari Medical SchoolBariItaly

Personalised recommendations